Atea Pharmaceuticals (AVIR) Treasury Shares (2019 - 2026)

Atea Pharmaceuticals' Treasury Shares history runs 7 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• On a quarterly basis, Treasury Shares rose 61.79% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 61.79% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, down 2.26% from the prior year.
• Treasury Shares advanced to $4.0 million in Q1 2026 per AVIR's latest filing, from $2.5 million in the prior quarter.
• Across five years, Treasury Shares topped out at $4.0 million in Q1 2026 and bottomed at $724970.0 in Q4 2022.
• The 5-year median for Treasury Shares is $2.5 million (2025), against an average of $2.2 million.
• Across the five-year window, Treasury Shares jumped 248.02% in 2024 and declined 10.94% in 2025, its largest moves.
• Year by year, Treasury Shares stood at $724970.0 in 2022, then changed by 0.0% to $724970.0 in 2023, then soared by 248.02% to $2.5 million in 2024, then fell by 2.26% to $2.5 million in 2025, then soared by 61.79% to $4.0 million in 2026.
• Per Business Quant, the three latest AVIR Treasury Shares figures stand at $4.0 million (Q1 2026), $2.5 million (Q4 2025), and $2.2 million (Q3 2025).